CBER Provides List of Guidances for 2024 Post author:PacConAdmin Post published:July 8, 2024 Post category:Uncategorized Post comments:0 Comments CBER has published an updated list of guidance topics for development during 2024. Source: Drug Industry Daily Tags: aaps Read more articles Previous PostLegislative Update — Week of July 8, 2024 Next PostSun Pharma Slapped With Warning Letter for Dadra Plant’s Multiple Violations You Might Also Like Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity January 26, 2024 FDA Issues Guidance on Biosimilar Interchangeability With Reference Products June 20, 2024 Have a Safe Trip: Clinical and Patient Alignment in Research with Psychedelics October 2, 2024 Leave a Reply Cancel replyCommentEnter your name or username to comment Enter your email address to comment Enter your website URL (optional) Save my name, email, and website in this browser for the next time I comment.
Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity January 26, 2024